Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational approach to drug discovery for human schistosomiasis

4 Jun 2021

Abstract excerpt

Human schistosomiasis is a debilitating, life-threatening disease affecting more than 229 million people in as many as 78 countries. There is only one drug of choice effective against all three major species of Schistosoma, praziquantel (PZQ). However, as with many monotherapies, evidence for resistance is emerging in the field and can be selected for in the laboratory. Previously used therapies include...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Helminth infection and control
Share to Parasites and Host Interactions
Share to Research on Leishmaniasis Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34111649
DOI: 10.1016/j.ijpddr.2021.05.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational approach to drug discovery for human schistosomiasisPMID 34111649Read ↗

Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites.Semantic proximity Read ↗

Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment.Semantic proximity Read ↗

Quinoxaline-based anti-schistosomal compounds have potent anti-plasmodial activitySemantic proximity Read ↗

Oxamniquine resistance alleles are widespread in Old World <i>Schistosoma mansoni</i> and predate drug deploymentSemantic proximity Read ↗

Quinoxaline-Based Anti-Schistosomal Compounds Have Potent Anti-Malarial ActivitySemantic proximity Read ↗

Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population.Semantic proximity Read ↗

Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical scaffold with broad anti-schistosomal activitiesSemantic proximity Read ↗

Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents.Semantic proximity Read ↗

<i>In silico</i> Repositioning of Approved Drugs Against <i>Schistosoma mansoni</i> Energy Metabolism TargetsSemantic proximity Read ↗

Schistosome ABC multidrug transporters: From pharmacology to physiologySemantic proximity Read ↗

Artemisitene protected against murine schistosomiasis japonica through anti-parasite activity and immune regulationSemantic proximity Read ↗

Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from Schistosoma Mansoni (SmSirt2)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.